This study investigates the causal relationships between antihypertensive and lipid-lowering drugs and inflammatory cytokines using a drug-targeted Mendelian randomization approach. By leveraging genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) data, the study evaluates the effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), HMG-CoA reductase inhibitors, PCSK9 inhibitors, and NPC1L1 inhibitors on key inflammatory cytokines such as IL-1β, TNF-α, CRP, and MCP-1. The findings aim to provide insights into the prevention and control of excessive inflammatory responses, particularly in patients with hypertension and dyslipidemia, by assessing the causal effects of these therapies.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Reduction in IL-1β Levels Due to ACE Inhibitors
Timeframe: Baseline to 12 months
Reduction in TNF-α Levels Due to ACE Inhibitors
Timeframe: Baseline to 12 months
Reduction in CRP Levels Due to ACE Inhibitors
Timeframe: Baseline to 12 months
Modulation of MCP-1 Levels Due to Statin Therapy
Timeframe: Baseline to 12 months
Modulation of MIP-1α Levels Due to Statin Therapy
Timeframe: Baseline to 12 months
Modulation of MIP-1β Levels Due to Statin Therapy
Timeframe: Baseline to 12 months
Reduction in IL-1β Levels Due to PCSK9 Inhibitors
Timeframe: Baseline to 12 months
Reduction in IL-6 Levels Due to PCSK9 Inhibitors
Timeframe: Baseline to 12 months